These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22106112)

  • 1. Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
    Callen JP
    Arch Dermatol; 2011 Nov; 147(11):1267-8. PubMed ID: 22106112
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
    Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
    Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
    Zeidi M; Kim HJ; Werth VP
    J Invest Dermatol; 2019 Feb; 139(2):324-332. PubMed ID: 30227141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
    Feldmann R; Salomon D; Saurat JH
    Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
    Ezra N; Jorizzo J
    Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
    González-Sixto B; García-Doval I; Oliveira R; Posada C; García-Cruz MA; Cruces M
    Actas Dermosifiliogr; 2010; 101(1):54-8. PubMed ID: 20109393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of antimalarial-refractory cutaneous lupus erythematosus.
    Callen JP
    Lupus; 1997; 6(2):203-8. PubMed ID: 9061669
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus.
    Kwatra SG
    J Am Acad Dermatol; 2015 Aug; 73(2):e79. PubMed ID: 26184008
    [No Abstract]   [Full Text] [Related]  

  • 11. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
    Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
    Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of smoking in cutaneous lupus erythematosus.
    Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
    Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know.
    Teboul A; Arnaud L; Chasset F
    J Dermatol; 2024 Jul; 51(7):895-903. PubMed ID: 38482997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L; Zhang L; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhabdomyolysis associated with quinacrine therapy in a patient with chronic cutaneous lupus erythematosus.
    Creel N; Werth V
    J Drugs Dermatol; 2005; 4(2):225-7. PubMed ID: 15776783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effect of hydroxychloroquine on cutaneous lupus erythematosus in a Japanese girl.
    Yamamoto T; Hiraiwa T
    J Dermatol; 2014 Apr; 41(4):357-9. PubMed ID: 24617496
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimal use of antimalarials in treating cutaneous lupus erythematosus.
    Wozniacka A; McCauliffe DP
    Am J Clin Dermatol; 2005; 6(1):1-11. PubMed ID: 15675885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
    Zeidi M; Chen KL; Patel J; Desai K; Kim HJ; Chakka S; Lim R; Werth VP
    Lupus; 2022 Apr; 31(4):472-481. PubMed ID: 35258358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.
    Mittal L; Werth VP
    J Am Acad Dermatol; 2017 Aug; 77(2):374-377. PubMed ID: 28711090
    [No Abstract]   [Full Text] [Related]  

  • 20. Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.
    Yan D; Borucki R; Sontheimer RD; Werth VP
    Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33082164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.